Close Menu

NEW YORK (GenomeWeb) – Arcis Biotechnology is aiming to raise £2 million (about $2.8 million) in a financing round to further develop a multiplex RNA-biomarker prostate cancer screening test.

The UK-based firm plans to use raised funds to finalize the prostate cancer test for use with patient urine samples by using its proprietary technology for stabilization of genetic material. Acris has already raised about £690,000 in capital for the assay.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Dec
04
Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).

Dec
11
Sponsored by
Roche

This webinar will address how two molecular laboratories are implementing tertiary analysis software to improve their precision oncology workflows.